Related Experiment Video
Updated: Jun 12, 2026
05:42
The Forced Swim Test as a Model of Depressive-like Behavior
Published on: March 2, 2015
TAAR6 variations possibly associated with antidepressant response and suicidal behavior.
Chi-Un Pae1, Antonio Drago, Jung-Jin Kim
1Department of Psychiatry, Kangnam St. Mary's Hospital, The Catholic University of Korea College of Medicine, Republic of Korea. pae@catholic.ac.kr
Psychiatry Research
|May 25, 2010
Summary
Genetic variations in TAAR6 may influence antidepressant treatment response and suicide risk in patients with depression. Specific TAAR6 genotypes were linked to better treatment outcomes and a history of suicide attempts.
Area of Science:
- Neuroscience
- Genetics
- Psychiatry
Background:
- Trace amines are brain regulatory elements implicated in depression.
- TAAR6, a trace amine-associated receptor, has known genetic links to bipolar and schizophrenic disorders.
Purpose of the Study:
- To investigate the association between TAAR6 genetic variations and depression clinical features.
- To explore the role of TAAR6 in antidepressant treatment response and suicide behavior.
Main Methods:
- Genotyping of 187 Korean depressive patients for five TAAR6 SNPs (rs7452939, rs4305745, rs6903874, rs6937506, rs8192625).
- Analysis of genotype-phenotype correlations and haplotype associations with clinical features, including treatment response and suicide history.
Main Results:
- rs6903874 T/T genotype carriers showed significantly better antidepressant improvement.
- rs6937506 C/C genotype was more frequent in patients without a history of suicide attempts.
- Haplotype G-T at rs7452939 and rs6937506 was associated with an increased risk of suicide behavior.
Conclusions:
- TAAR6 genetic variations may play a role in antidepressant response and suicide behavior in depressive disorder.
- Further research is warranted to confirm these findings, considering potential biases and heterogeneity.
Related Concept Videos
01:23Antidepressant Drugs: MAOIs and Other Agents
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:28Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Tricyclic Antidepressants (TCAs), including Desipramine (Norpramin), Imipramine (Tofranil), Clomipramine (Anafranil), and Amitriptyline (Elavil), inhibit serotonin and norepinephrine reuptake and also block other receptors. They are used for depression, pain conditions, and insomnia. Common adverse effects include anticholinergic effects, sedation, orthostatic hypotension, and weight gain. They have a narrow therapeutic window and so require plasma-level monitoring. Abrupt discontinuation can...
01:25Antidepressant Drugs: Overview
Antidepressant drugs are a class of medications primarily used for treating various mood disorders, including major depression, anxiety disorders, and other related conditions. These medicines work by modulating the neurotransmitter balance within the brain, alleviating depressive symptoms. Antidepressants can be broadly categorized into several groups according to their mechanism of action and chemical structure: Selective Serotonin Reuptake Inhibitors (SSRIs), Serotonin-Norepinephrine...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:21G-protein Coupled Receptors
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.